Description of the medicine: Pyromecain (Pyromecainum)
Pyromecain (Pyromecainum). 2, 4, 6-Trimethylanilide-1-butyl-pyrrolidine-carboxylic-2-acid hydrochloride, or 1-butyl-2, 4, 6-trimethyl-2-pyrrolidine-carboxanilide.
Synonyms: Bumecain hydrochlorid, Bumecaini hydrochloridum, Pirromecain.
Crystalline powder, white or white with a slight cream tint. Soluble in water, easy in alcohol. Solutions (pH of a 2% solution of 4, 4 - 5, 4) are prepared on an isotonic sodium chloride solution, sterilized at +100 ° C for 30 minutes.
Local anesthetic. The chemical structure is similar to trimecaine. It also has an antiarrhythmic effect.
As an anesthetic used for surface anesthesia.
In ophthalmic practice, use a 0.5% solution of 1 to 2 drops; in otorhinolaryngological practice - 1 - 5 ml of 1 - 2% solution (if necessary, add 0.1% adrenaline hydrochloride solution, 1 drop for every 2 - 3 ml of pyromecain); for anesthesia during endoscopic examinations - 2 - 5 ml of a 2% solution; in dentistry - 1 - 5 ml of 1 - 2% solution or 5% pyromecainic ointment.
As an antiarrhythmic agent, pyromecain is prescribed for ventricular arrhythmias: for myocardial infarction, intoxication with cardiac glycosides, etc. Pyromecain is administered intravenously in the form of a 1% solution in a 5% glucose solution, slowly at a speed of 1 ml / min at a dose of 50 - 100 mg (5 - 10 ml of 1% solution) for 3 to 5 minutes. For long-term therapy, pyromecain is administered intravenously slowly at a rate of 1 ml / min at a dose of 100 mg (10 ml of solution) 2–3 times with an interval between administrations of 15–20 minutes. The achieved antiarrhythmic effect is supported by the drip of the drug at a rate of 2–3 mg / min (8–12 drops per minute). In acute myocardial infarction, pyromecain is administered: 1) at a dose of 100-150 mg (10-15 ml of a 1% solution) intravenously, streamwise slowly for 3 to 5 minutes (a one-time bolus); 2) at a dose of 100 mg (10 ml of a 1% solution) 2 times with an interval between administrations of 15 to 20 minutes against the background of drip administration - a two-time bolus against the background of infusion.
The duration of the infusion depends on the nature and course of the process and the effectiveness of the therapy.
The average single dose for intravenous administration of a 1% solution of 0.1 g (100 mg).
The highest daily dose when injected into a vein is 1.5 g (1500 mg).
When pyromecaine is used, general weakness, nausea, vomiting, dizziness, drop in blood pressure, collaptoid state are possible. If necessary, vasoconstrictors are recommended. Intravenous administration should be carried out only in a hospital setting.
Forms of release: 0.5%; 1% and 2% solutions in ampoules of 10 ml, 1% solution in 5% glucose solution for intravenous administration (Sol. Ruromecaini 1% cum glucoso pro injectionibus) in ampoules of 10 ml; 5% pyromecainic ointment.
Storage: List B.
Pyromecainic ointment 5% (Unguentum Pyromecaini 5%). It is used as an anesthetic for inflammatory diseases of the oral mucosa. Apply a thin layer to the painful area once or twice for 2 to 5 minutes. The dose of ointment should not exceed 1 g.
Release form: in tubes on 30 g.